The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
Authors
Keywords
Neovascular AMD, Ranibizumab, Treat and extend regimen, Intra-retinal fluid, Sub-retinal fluid
Journal
BMC Ophthalmology
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-24
DOI
10.1186/s12886-016-0207-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Erratum: Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results
- (2015) C Gianniou et al. EYE
- Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
- (2015) Jennifer J. Arnold et al. OPHTHALMOLOGY
- ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION
- (2014) Farshad Abedi et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
- (2013) James E. Frampton DRUGS & AGING
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
- (2013) Brandon G. Busbee et al. OPHTHALMOLOGY
- Genetic Influences on the Outcome of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-related Macular Degeneration
- (2013) Farshad Abedi et al. OPHTHALMOLOGY
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
- (2013) Juan E. Grunwald et al. OPHTHALMOLOGY
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
- (2013) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- Comparison of Outcomes from a Phase 3 Study of Age-Related Macular Degeneration with a Matched, Observational Cohort
- (2013) Mark C. Gillies et al. OPHTHALMOLOGY
- A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION
- (2013) Nicholas Toalster et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
- (2011) Frank G. Holz et al. OPHTHALMOLOGY
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact
- (2010) Omesh P. Gupta et al. OPHTHALMOLOGY
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED
- (2010) Hassiba Oubraham et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
- (2009) Geeta A. Lalwani et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now